In isolated rat liver tissue, vasopressin does not change how much fat the liver produces from sugar and lactate, indicating it does not play a direct role in fat synthesis under these metabolic conditions.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether vasopressin exposure consistently affects hepatic lipid synthesis in humans across clinical and experimental settings.
A systematic review and meta-analysis of all human studies (RCTs, metabolic chamber studies) measuring de novo lipogenesis via stable isotope tracers in response to vasopressin infusion (0.01–0.04 U/min) versus control, with at least 5 studies and 120 total participants.
An RCT could determine whether vasopressin infusion directly alters hepatic fat synthesis rates in humans under controlled metabolic conditions.
A double-blind, crossover RCT in 20 healthy adults, receiving 2-hour infusions of vasopressin (0.02 U/min) or saline after a standardized high-carbohydrate meal, with hepatic de novo lipogenesis measured via [13C]acetate tracer and liver fat via MRI.
A cohort study could assess whether individuals with chronically elevated vasopressin (e.g., due to dehydration or SIADH) develop higher liver fat accumulation over time.
A 5-year prospective cohort of 400 adults with varying vasopressin levels (measured quarterly), tracking liver fat via MRI and de novo lipogenesis via tracer, adjusting for alcohol, diet, insulin resistance, and BMI.
A case-control study could compare vasopressin levels and liver fat synthesis rates in individuals with NAFLD versus healthy controls.
A case-control study comparing 80 adults with biopsy-confirmed NAFLD to 80 matched controls, measuring fasting plasma vasopressin and hepatic de novo lipogenesis via [2H2O] tracer, with exclusion of alcohol use and diabetes.
A cross-sectional study could show whether plasma vasopressin levels correlate with liver fat content or lipogenesis markers in a population.
A cross-sectional study measuring plasma vasopressin, liver fat via MRI, and serum lipogenesis markers (e.g., FASN, ACC) in 250 adults undergoing routine metabolic screening.